Skopos Bio

Melbourne-based Peter MacCallum Cancer Centre spinout designing targeted radioactive molecules to treat hard-to-treat cancers, starting with prostate cancer.

Industry
biotechnology, radiopharmaceuticals
Location
Melbourne, VIC, Australia

About

Skopos Bio designs radioactive molecules that seek out and bind to cancer cells, delivering radiation to tumours while largely sparing healthy tissue, starting with hard-to-treat prostate cancer. It was spun out of the Peter MacCallum Cancer Centre in Melbourne and founded by Professor Michael Hofman and Associate Professors Mohammad Haskali and Luc Furic, with Jeevan Virk as Chair, according to Tenmile.

Funding history

RoundDateAmountLead
Seed 20262026-09-30Tenmile, Tin Alley Ventures, Yosemite

Investors

Sources

Last verified:

  1. https://www.linkedin.com/posts/tenmile_our-newest-portfolio-company-skopos-bio-activity-7511205761151115264-iEGA
    Type: official investor website. Accessed 2026-10-12.
    Tenmile LinkedIn post dated 2026-09-30 (23:30 UTC). Says Skopos Bio launched with an AUD$12m seed raise, that Tenmile co-leads the round with Tin Alley Ventures and Yosemite, and that the company is a Peter MacCallum Cancer Centre spinout founded by Michael Hofman, Mohammad Haskali and Luc Furic, with Jeevan Virk as Chair.
  2. https://www.founderland.ai/articles/skopos-bio-raises-83m-for-radiopharmaceutical-cancer-therapy-mux6psve
    Type: reputable publication. Accessed 2026-10-12.
    Founderland article dated 2026-10-06. Reports that the Melbourne Peter MacCallum Cancer Centre spinout raised A$12 million, which it converts to US$8.3 million, from Tenmile, Tin Alley Ventures and Yosemite, and that the three co-led the round.
  3. https://www.finsmes.com/2026/10/skopos-bio-raises-12m-in-seed-funding.html
    Type: reputable publication. Accessed 2026-10-12.
    FinSMEs article dated 2026-10-12. Confirms the Melbourne, Victoria location and the seed round backed by Tenmile, Tin Alley Ventures and Yosemite. It writes the amount as $12m without naming the currency.